Your browser doesn't support javascript.
loading
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury, Manal; Mladenov, Radoslav; Nachreiner, Thomas; Pham, Anh-Tuan; Hristodorov, Dmitrij; Di Fiore, Stefano; Helfrich, Wijnand; Pardo, Alessa; Fey, Georg; Schwenkert, Michael; Thepen, Theophilus; Kiessling, Fabian; Hussain, Ahmad F; Fischer, Rainer; Kolberg, Katharina; Barth, Stefan.
Afiliação
  • Amoury M; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Mladenov R; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Nachreiner T; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Pham AT; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Hristodorov D; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Di Fiore S; Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Helfrich W; Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Pardo A; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Fey G; Department of Biology, Friedrich Alexander University Erlangen-Nuremberg, Germany.
  • Schwenkert M; Bio-Rad AbD Serotec GmbH, Puchheim, Germany.
  • Thepen T; Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Kiessling F; Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Germany.
  • Hussain AF; Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, Germany.
  • Fischer R; Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
  • Kolberg K; Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany.
  • Barth S; Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
Int J Cancer ; 139(4): 916-27, 2016 08 15.
Article em En | MEDLINE | ID: mdl-27037627
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Proteínas Recombinantes de Fusão / Proteínas tau / Anticorpos de Cadeia Única / Neoplasias de Mama Triplo Negativas / Proteínas de Membrana / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Proteínas Recombinantes de Fusão / Proteínas tau / Anticorpos de Cadeia Única / Neoplasias de Mama Triplo Negativas / Proteínas de Membrana / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2016 Tipo de documento: Article